Join Knight Therapeutics for Their Q3 Financial Results Review
Knight Therapeutics Inc. (TSX: GUD) a prominent specialty pharmaceutical company, is set to unveil its financial performance for the third quarter of 2024. The eagerly awaited results will be disclosed on the morning of a specified date, well ahead of market hours, allowing investors and stakeholders to assess the company's financial health directly.
Upcoming Conference Call Details
In light of the recent financial performance announcement, Knight Therapeutics encourages everyone interested in the company's trajectory to participate in a related conference call. This interactive session will provide a platform for insights into the company's advancements and growth plans.
Key Information on the Conference Call
Participants can mark their calendars for the following details:
- Date: A specified date
- Time: 8:30 a.m. ET
- Telephone Connection: For listeners in North America, a toll-free line is available at 1-800-836-8184, while international participants can dial 1-289-819-1350.
Webcast Availability
In recognition of the technological advances in communication, Knight Therapeutics will also offer an audio webcast for those who wish to join virtually. This option provides a convenient and accessible way for everyone to stay informed.
About Knight Therapeutics Inc.
Headquartered in Montreal, Canada, Knight Therapeutics Inc. is a key player in the specialty pharmaceutical industry. The company aims to acquire, in-license, and market pharmaceutical products specifically tailored for Canadian and Latin American markets. Knight operates through several Latin American subsidiaries, including United Medical, Biotoscana Farma, and Laboratorio LKM, ensuring robust market penetration and effective distribution.
Current Operations and Growth Strategies
Knight Therapeutics continues to expand its portfolio and geographic reach. Their commitment to enhancing the healthcare landscape is evident as they introduce innovative solutions for unmet medical needs in the Latin America region. As the company prepares for its upcoming announcements, investors eagerly anticipate insights into how these efforts are translating into financial results.
Our Investor Relations Team
For any inquiries or further information regarding Knight Therapeutics, stakeholders are encouraged to reach out directly to their investor relations team:
- Samira Sakhia, President & CEO - T: 514.484.4483
- Arvind Utchanah, CFO - T: +598.2626.2344
Both Samira and Arvind are available to address any questions and provide further clarity on the company's operations and initiatives.
Frequently Asked Questions
What are Knight Therapeutics' core business focuses?
Knight Therapeutics specializes in acquiring and commercializing pharmaceutical products primarily for Canada and Latin America.
When will Knight Therapeutics release its Q3 financial results?
The release is scheduled for a specified date before market opening, allowing for timely analysis.
How can I participate in the conference call?
Interested parties can dial the provided toll-free number or join via the designated audio webcast to stay updated.
Who can I contact for investor-related inquiries?
Samira Sakhia, the CEO, and Arvind Utchanah, the CFO, can be contacted for any investor relations questions.
What subsidiaries does Knight have in Latin America?
The company operates through subsidiaries such as United Medical, Biotoscana Farma, and Laboratorio LKM, enhancing its market presence.